Personnel de l'université
Elise CHIFFOLEAU
Chargée de Recherche Hors Classe INSERMCoordonnées
CR2TI CHU Hotel Dieu 30 Bd Jean Monnet 44093 Nantes cedex 01
- Elise.Chiffoleau@univ-nantes.fr
- Site internet
- https://cr2ti.univ-nantes.fr/research/team-1
Discipline(s) enseignée(s)
Mononuclear phagocytes, ImmunoPathology, ImmunoVirology
Thèmes de recherche
- Our team scientific activity is committed to basic and translational research and aims at better understanding the mechanisms of immune tolerance and the role of dendritic cells (DCs) in immunoregulation in order to identify new cellular and molecular therapeutic targets. Recently, the theme has then been expanded to the role of DCs and Mononuclear Phagocytes (MNP) in inflammatory diseases and in host-virus interactions in the context of transplantation and immunodepression.
- We further developed new functional genomic approaches to better characterize MNP diversity and their role in immunopathology. This strategy to enlarge our research topics and expertise aimed to increase the interdisciplinarity of the team and allowed new funding opportunities (H2020, EU/ERA NET, ITN INSTRUCT, iSITE NEXT, ANRs). There is also a strong commitment to translational research and clinical development with filed patents and industrial partnerships.
- Recently, we contributed to the understanding of the molecular basis of immunoregulatory MNP functions in transplantation (Cell Metabolism, 2019, Kidney International 2023), anti-tumor immunity (Cancer Cell 2019, Science Advances 2022) and inflammatory diseases (Cell 2019) as well macrophages in lung infection (Nature Immunology 2020). We also demonstrated our ability to translate some of our findings to the clinic (The Lancet 2020).
Specific projects:
CLEC-1 in MNPs : immunopathology and therapeutic potential (PI: E Chiffoleau): We previously showed that the innate C-type Lectin receptor CLEC-1 is a receptor of necrotic cells and acts as an immune checkpoint by limiting the cross-presentation of dead cell-associated antigens by cDC1 to CD8+ T cells and that its blockade with mAbs enhances anti-tumor immunity (Drouin et al. Science Advances 2022) (Ligeron et al. The Journal of Immunology 2024) (ANR PRCE 2019-2023, Fondation ARC 2023-2024, partnership with OseImmunotherapeutics ANRT CIFRE OSEI (2020-2023 and 2023-2026). We also demonstrated that CLEC-1 promotes early IFN response in cDC1s and favors immune dysregulation during sepsis in mice (Ogor et al. iScience 2026) (ANR PRC and Région PdL 2023-2026). We now aim to study in depth the molecular mechanisms of CLEC-1 in cDC1 cross-presentation (cytokine and chemokine expression, phagosome maturation) and particularly in the context of cancer (PLBIO INCa (2026-2029). Staff: Despoina Koumantou (Postdoc 100%).
Activités / CV
/ 1
Mis à jour le 25 août 2026.